A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge with Virulent Wild-Type Bordetella pertussis (CHAMPION-1 study)

In this study, we are trying to find out how we can best protect people against pertussis (more commonly known as whooping cough). Pertussis is a highly contagious infection of the lungs and airways, caused by bacteria (small organisms which can reproduce and cause illness) called Bordetella pertussis (B. pertussis). The groups of people most severely affected by pertussis are babies, the elderly, people with chronic medical conditions that affect the lungs and heart, and people who are immunocompromised (unable to respond normally to an infection).

COVID-19 Challenge Study (COV-CHIM 01)

What is the purpose of this study and why participate?

SARS-CoV-2 is the virus responsible for COVID-19 disease. Recent roll out of licensed vaccines is a positive step towards fighting COVID-19. However, we don’t know how long protection after COVID-19 infection and/ or vaccination lasts and why some people can get infected a second time..